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1. Introduction 
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults1. Over 
the past twenty years, the studies on the pathogenesis and prognosis of AML have made 
considerable progress.  
Clinically, patients with AML typically present with signs or symptoms of bone marrow 
failure, although sometimes they can present with symptoms of leukostasis with pulmonary 
or neurological dysfunction. Rarely, patients will present with primary extramedullary 
disease, which should be approached in the same way as systemic AML.  
A certain number of factors can be involved in the etiology of AML: as an example, 
exposure to ionizing radiation and long-term exposure to benzene are known risk factors. 
AML could be part of the natural history of patients with congenital disorders of DNA 
repair, such as the Fanconi's anemias; also the myeloproliferative disorders (MPD) and 
myelodysplastic syndromes (MDS).  
AML is a heterogeneous disease; standard treatments may be applied to biologically distinct 
subgroups, resulting in different treatment outcomes. However, less than one-third of all 
adult patients with AML can be cured even to this date. The treatment of refractory, 
relapsed and elderly AML remains a major challenge. In recent years, new regimens and 
novel agents are being studied in an effort to improve complete remission (CR) rate and 
overall survival. The concept of risk-adapted therapy allows for recognition of this biologic 
diversity by incorporating key biologic features, such as cytogenetic and molecular markers, 
when formulating treatment regimens and investigating emerging targeted therapies based 
on disease characteristics. Although AML has been the focus of significant laboratory and 
clinical investigation, it remains difficult to treat, perhaps partly because of the fundamental 
nature of the disorder, which requires substantial institutional resources to adequately deal 
with the complications of bone marrow failure and sustain patients through periods of 
intensive therapy. Several large studies have helped categorize chromosomal abnormalities 
into good-, intermediate-, and poor-risk groups2-5. This hierarchical system of karyotype 
classification is predictive value across different age groups in de novo and secondary AML. 
It was also found to retain prognostic significance across the different treatment modalities 
of chemotherapy and autologous and allogeneic bone marrow transplantation. Generally, 
the poor-risk or unfavorable group includes those with complex karyotypes (> 3-5 
abnormalities), chromosome 5 or 7 abnormalities, or chromosome 3q abnormalities. The 
results for these patients are dismal, with standard chemotherapy causing some to advocate 
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patients undergoing stem cell transplantation in first remission3,5. In contrast, such an 
“aggressive” approach as allogeneic stem cell transplantation in first complete remission 
(CR) is generally not recommended in patients with good-risk or favorable cytogenetics. 
Included in this category are those with t(15;17), t(8;21), t(16;16), and inv(16) translocations6. 
Acute promyelocytic leukemia (APL), defined by the t(15;17) translocation, has a distinct 
biology, and combinations of dose-intensive anthracyclines, all-trans-retinoic acid (ATRA), 
and arsenic trioxide may be curative for most patients.  
Age was not, however, found to be the only significant factor affecting treatment outcomes. 
Although supportive measures have generally improved within the past 20 years, the drugs 
that form the backbone of standard AML chemotherapy remain essentially unchanged.  
2. Therapy 
2.1 High dose daunorubicin  
The standard induction regimen for newly diagnosed AML consists of daunorubicin (DNR) 
45 mg/m2 intravenously for 3 days and cytarabine (AraC) 100 mg/m2 by continuous 
infusion for 7 days. With this regimen 60% to 80% of young adults and 40% to 60% of older 
adults can achieve a CR7. 
Several major studies, particularly Cancer and Leukemia Group B (CALGB) 9621 and the 
French ALFA 9801 studies, have shown that higher doses of DNR (80 or 90 mg/m2) can be 
administered safely8,9. Recently, there are two major prospective studies compared DNR 
90 mg/m2 with 45 mg/m2 in the induction regimen10,11. Eastern Cooperative Oncology 
Group (ECOG) studied 657 AML patients between the age of 17 to 6010. The study showed 
significantly higher CR rate for patients receiving 90 mg/m2 (70% versus 57%). More 
importantly, overall survival (OS) was significantly prolonged (23.7 vs 15.7 months). The 
Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON)/Swiss Group for 
Clinical Cancer Research (SAKK) compared DNR 90 mg/m2 versus 45 mg/m2 in 813 
patients older than 60 years11. The results showed that CR rate was 64% and 54% 
respectively, while CR rate after only one course of treatment was 52% and 35% 
respectively. The OS rate was not significantly different for the whole group. However, 
for the patients between the age of 60 to 65, the OS rate was significantly better in the high 
dose group (38% vs 23%). The rates of serious adverse events were similar in the two 
treatment groups in both studies. 
Based on historic trials and the most recent prospective studies, the 45 mg/m2 of DNR 
should no longer be the standard-dose for induction therapy. Instead, for induction therapy 
of all age groups, DNR dose should be between 60 mg/m2 to 90 mg/m2 for 3 days, but the 
exact optimal dosage remains to be established12. 
2.2 New formulations of old agents 
Liposomal encapsulation of drugs can reduce the toxicity and decrease drug doses with 
controlled-release effect. CPX-351 is a liposomal formulation that encapsulates cytarabine 
and daunorubicin at a 5:1 molar ratio. A recently completed phase 1 study13 recommended 
that 90-minute infusions of 101 u/m2 be given on days 1, 3, and 5 (1 u = 1 mg Ara-C + 0.44 
mg DNR). The results showed that liposomal encapsulation of this chemotherapy changed 
the safety profile by reducing non-hematologic toxicities including hair loss, gastrointestinal 
toxicities and hepatic toxicity, while retaining hematopoietic cytotoxicity.  
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2.3 Targeted therapy regimens 
In recent years, encouraging results have been achieved by using monoclonal antibodies for 
targeted therapy of the solid and hematologic malignancies. CD33 antigen is expressed in 
more than 90% of AML cells, while expression in normal tissue is very weak. Gemtuzumab 
ozogamycin (GO) is chemoimmunotherapy agent consisting of a monoclonal antibody 
against CD33 conjugated to calichemycin. GO triggers apoptosis when hydrolyzed in the 
leukemic blasts. GO has been approved by the U.S. FDA for the treatment of the elderly (> 
60 years) with AML in first relapse. Standard induction regimen with or with out GO were 
compared in a randomized study which enrolled 1115 younger adults with AML. The 
preliminary analysis showed a similar CR rate in both arms, but a significantly improved 
DFS among patients receiving GO--51% versus 40% at 3 years (P = .008)14. However, due to 
toxicity concern and the lack of definite survival benefit after longer follow-up, FDA has 
recently withdrawn its approval.   
A phase II study of My-FLAI aiming to assess toxicity and efficacy was done in patients 
with newly diagnosed AML aged more than 60 years15. The results showed that the four 
drug regimen My-FLAI was well tolerated in an elderly AML population, but its efficacy 
did not appear to be superior to that of standard "3+7" regimen15. 
2.4 New agents nucleoside analogues 
Nucleoside analogues transform into active metabolites (triphosphate nucleoside analogues) 
in the cells and inhibit DNA synthesis. Clofarabine is a new nucleoside analogue, a potent 
inhibitor of both ribonucleotide reductase and DNA polymerase. At the 2009 ASH meeting, 
a few studies on Clofarabine were reported16-18, either clofarabine alone or in combination 
with low-dose Ara-C, or high-dose Ara-C with the monoclonal antibody GO in the 
treatment of elderly AML or relapsed AML. Two novel nucleoside analogues, sapacitabine 
and elacytarabine, were also reported for the therapy of the elderly with refractory or 
relapsed AML19,20. 
2.5 FLT3 inhibitors (Fms-like tyrosine kinase 3 inhibitors) 
The Flt3-internal tandem duplication (ITD) can be found in approximately 30% of all AML 
patients and confers a poor risk status characterized by an increased relapse rate and poor 
overall survival21,22. Moreover, Flt3-ITD-positive AML patients relapsing after allogeneic 
stem cell transplantation (SCT) have very limited therapeutic options. Sorafenib is a 
multikinase inhibitor that is approved for the treatment of metastatic renal cell and 
hepatocellular carcinoma. Sorafenib monotherapy has significant clinical activity in Flt3-ITD 
positive relapsed and refractory AML23,24. 
In addition, combination therapy with sorafenib was shown to be effective in reducing 
mutant clones in patients with FLT3 mutations but was not able to completely eradicate 
them25. These data suggest that sorafenib can achieve temporary disease control, but should 
be integrated into induction and consolidation regimens to achieve maximal outcome  
2.6 Farnesyl-Transferase Inhibitor (FTI) 
In recent years, studies have shown that Ras gene mutation plays an important role in 
leukemogenesis26. By inhibiting farnesyl protein transferase, FTI prohibits the Ras protein 
farnesylation, schizolysis and carboxyl methylation, thus disrupting the critical Ras 
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signaling pathway. Tipifarnib (± bortezomib) may represent an important option in a subset 
of high risk/frail AML patients27. 
2.7 Histone deacetylase inhibitors 
Vorinostat is a new anti-cancer agent inhibiting histone deacetylase and has been shown to 
have some efficacy in treatment of AML28. Vorinostat in combination with idarubicin and 
ara-C has synergistic antileukemia activity in a sequence dependent fashion. Therefore, the 
combination of vorinostat, idarubicin and cytarabine is safe and active in AML. CR or CRi 
was achieved by 18% pts with MDS, 8% with relapsed/refractory AML, and 36% with 
untreated AML29. The combination of vorinostat with decitabine either concurrently or 
sequentially is possible without significant toxicity and shows activity in MDS and 
untreated AML30. 
2.8 DNA Methyl-transferase inhibitors  
The demethylating agents 5-azacytidine and Decitabine are remarkably active, even at low 
doses with mild hematologic toxicity, in patients with high-risk MDS. This disease shares 
many poor prognostic features with AML of the elderly. 
Decitabine: Decitabine inhibits DNA methyltransferase, leading to DNA 
hypomethylation and cell differentiation or apoptosis. A combination of decitabine and 
GO was found to be effective with low side effects in previously untreated or 
refractory/relapsed AML patients, especially in elderly patients31. The toxicities were 
minimal and the regimen can be safely delivered to older patients. The pioneering study 
by Pinto and coworkers32 described 12 patients with AML who received Decitabine (90-
120 mg/m2 as a 4-h infusion 3 times daily for 3 days, repeated every 4–6 weeks). Three 
patients achieved a complete remission (CR) and one a partial remission (PR) ; extra-
hematological toxicity was generally mild. Preliminary results of a trial using low-dose 
decitabine in older patients with AML were reported more recently33: Cashen and 
coworkers gave the drug over 1 h on 5 consecutive days (20 mg/m2 per day), repeated 
every 28 days. Fifty-five patients with a median age of 74 years old were enrolled and 
treated with a median of three cycles : overall response rate was 25% (complete response 
rate, 24%) and median survival was 7.7 months.   
5-Azacytidine: despite the fact that more than 100 trials of high dose 5-azacytidine were 
performed in AML in the 1970s and 1980s (mostly in combination with other 
chemotherapies), a very limited number of trials using this drug in AML have been 
published. When the CALGB compared the use of 5-Azacytidine to best supportive care in 
people with all risk groups of MDS, there was a trend toward a survival benefit in those 
patients who received the 5-Azacytidine34. There was a decrease in the P15 methylation 
associated with response. 5-azacytidine was approved by the FDA in 2004 for the treatment 
of MDS (all subtypes). Phase II studies of 5-azacytidine in MDS had been initiated by 
Silverman and the CALGB35 (7 daily administrations of 75 mg/m2, total dose 525 mg/m2, 
repeated every four weeks); overall response rate of 49% was obtained, with 12% CRs and 
median response duration of 14.7 months. A pivotal phase III study of the CALGB34 
compared subcutaneous 5-azacytidine randomized against best supportive care (BSC), with 
the possibility of “cross-over” from BSC in case of progressive disease. An overall response 
rate of 60%, with 7% CRs and 16% PRs and median response duration of 15 months was 
achieved in the experimental arm. Quality of life was also significantly improved in 5-
www.intechopen.com
 
Therapy of Acute Myeloid Leukemia 
 
115 
azacytidine treated patients. Side effects included mainly myelosuppression and associated 
effects, particularly during the first cycles. Non-hematological toxicties, e.g. nausea and 
vomiting, were rare, but skin reactions occurred more frequently. The French ATU 
program36 performed a retrospective analysis of 184 patients with refractory or relapsed 
AML who received azacytidine. 11% of the patients responded (7%CR, 3%CRi, 1% PR). It 
appears that single agent azacytidine has only limited activity in AML patients relapsed or 
refractory to intensive frontline therapy. Combination of azacitidine with bortezomib or 
low-dose GO was also studied in relapsed or refractory AML patients37,38. In a large 
confirmatory trial39, 5-azacytidine was compared to conventional treatment as determined 
prior to randomization by the treating physician (either BSC, low-dose ara-C, or induction 
chemotherapy). Of 358 patients included, 179 were randomized to 5-azacytidine, 179 to 
conventional care (105 to BSC, 49 to low-dose ara-C, 25 to standard induction 
chemotherapy). Study drug was administered for a median of 9 cycles. 28.5% of patients in 
the experimental arm achieved CR or PR. Median survival was 24.4 months in the 5-
azacytidine group compared to 15 months in the conventional care group (P=0.0001), with a 
doubling of the 2-year survival (50.8 vs. 26%, P<0.0001). 
3. Valproic acid, an inhibitor of Histone Deacetylases (HDACs) 
Valproic acid (VPA) is an inhibitor of class I HDACs. Over the last 5 years, the drug has 
been studied as either a single agent or in combination with various drugs including ATRA. 
VPA has provided a 50% overall response rate in low-risk MDS and a lower rate of response 
in high-risk MDS40 and AML41,42. The contribution of ATRA probably was modest. Thus, the 
role of single-agent VPA may be rather limited in AML. Nevertheless, the drug in 
combination with an active drug such as decitabine, may have enhanced activity, as 
demonstrated in vitro43. A large phase II study of AML and MDS performed at the MD 
Anderson Cancer Center demonstrated the feasibility of DAC combined with 10 days of 
intravenous VPA44. 
3.1 Other agents in early clinical development 
Voreloxin: is a first-in-class anticancer quinolone derivative that intercalates DNA, inhibits 
topoisomerase II, and induces apoptosis. A preliminary report on a voreloxin trial revealed 
clinical activity in previously untreated elderly (age ≥ 60) AML patients who are unlikely to 
benefit from standard chemotherapy45 
Amonafide L-malate (AS1413): is a unique DNA intercalator, in combination with cytarabine 
produced a high complete remission rate and durable responses in both older and younger 
patients with secondary AML46. 
Ezatiostat hydrochloride: is a glutathione S-transferase P1-1 inhibitor, evaluated in 
myelodysplastic syndrome. In a phase I/II study47, trilineage responses were observed in 4 
of 16 patients (25%) with trilineage cytopenia. These responses were accompanied by 
improvement in clinical symptoms and reductions in transfusion requirements.  
Lenalidomide: (LEN) is one of the three new drugs approved by the U.S. FDA to treat 5q-low-
risk MDS. Lenalidomide has demonstrated multiple mechanisms of action48. In a recent 
phase II study49 of LEN in combination with Ara-C and daunorubicin in high risk 
MDS/AML with del 5q, 28% responded. The results show that LEN combined with 
chemotherapy in AML treatment is feasible, without significant additional toxicity.  
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Ribavirin: The eukaryotic translation factor, eIF4E, is over expressed in AML, and is 
associated with poor prognosis. Ribavirin is clinically used as an antiviral molecule, and its 
structure is similar to the m(7)G cap of mRNA, thus inhibiting eIF4E-induced export and 
translation of sensitive transcripts50.  
ARRY-520: The kinesin spindle protein (KSP) plays a major role for the assembly of a normal 
bipolar spindle and is also required for cell cycle progression through mitosis. ARRY-520 is 
a potent, selective inhibitor of KSP51.  
AZD1152: Aurora B kinase plays a major role in regulating mitosis and is over expressed in 
AML. Also it’s a highly potent and selective inhibitor of aurora B kinase. It has been shown 
to inhibit tumor growth in vivo52.  
AZD6244: is one of the orally bioavailable small molecule inhibitors of MEK kinase53-55. 
Terameprocol: The inhibitor of apoptosis protein (IAP), survivin, is a key regulator of cell 
cycles. In leukemic cells, survivin is involved in leukemia cell survival and resistance to 
chemotherapeutics and Flt-3 inhibitors56.  
3.2 Allogeneic Stem Cell Transplant (allo-SCT) 
In patients with AML, published guidelines and treatment recommendations are usually the 
basis for starting the work-up process for allo-SCT57. However, only consistent 
recommendations would allow a standardized clinical practice.  A comprehensive 
systematic literature search could allow to evaluate the best available evidence from 
controlled clinical trials. The following aspects were selected for systematic comparison: 
factors for risk assessment and categorization, role of type of donor, significance of allo-SCT 
in first or second complete remission and in relapse/progressive disease; and role of 
reduced intensity conditioning (RIC) regimens. The use of myeloablative and non-
myeloablative allogeneic stem cell transplant represents a potentially curative approach for 
patients suffering from acute and chronic leukemias such as AML. Thousands of patients 
have been treated worldwide by the transplant of hematopoietic stem cells from a related or 
unrelated donor (available at: http://www.bmdw.org). However, it is obvious that not all 
patients diagnosed with AML will benefit from allogeneic stem cell transplant. Therefore, 
the establishment of definitive, clear, evidence-based recommendations as to which patients 
are likely to benefit from transplant is needed. Several interesting findings emerge when 
comparing recommendations for transplant in key guidelines: (i) for patients with relapsed 
or refractory disease, donor availability should be explored and patients should receive 
transplant, though this is not based on reliable evidence from genetically randomized 
studies; (ii) patients in CR1 with intermediate-or high-risk disease and an available matched 
related donor should receive allogeneic stem cell transplant (intermediate-risk: allo-SCT, 
reasonable option); (iii) for patients who lack a family donor the recommendations are not 
consistent; (iv) allogeneic transplant with reduced conditioning in patients with AML is 
feasible, but the superiority over standard therapeutic regimens is not yet proven. At this 
point in time, there is no doubt that hematopoietic allogeneic stem cell transplant is an 
effective clinical procedure with a curative ability, but intensive induction and consolidation 
chemotherapy may also be sufficient for many patients. But it is likely that only well-defined 
subgroups of patients with AML will benefit from stem cell transplant. The delineation of 
these specific patient groups will be a major objective of future clinical trials. 
Transplant of patients with AML in first CR: in patients who achieved CR, the role of allo-
SCT is still under discussion. A variety of clinical studies have tried to evaluate the benefit 
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of transplant in this situation, but most studies were non-randomized, non-controlled 
trials3,5,6. Only a few trials that were analyzed based on donor availability (‘genetic’ or 
‘biological’ assignment) were useful as supporting evidence in the guideline 
recommendations, which were mainly based on cytogenetic risk factors. These methods of 
patient assignment often introduce biases. Therefore, some guidelines regard these trials as 
level II (cohort study) and not as level I evidence (randomized clinical trials). Cassileth et 
al.58 reported a study of patients with AML aged 16–55 years with complete remission after 
induction therapy who were offered allogeneic transplant if a genotypically or 
phenotypically human leukocyte antigen (HLA)-matched or single-antigen mismatched 
family donor was available (n=113). Remaining patients were randomized to autologous 
transplant (n=116) or a single course of high-dose cytarabine (n=117). The distribution of 
karyotypes did not differ significantly among treatment groups. After a median follow-up 
time of 4 years, the authors found no evidence for significant differences in disease-free 
survival (DFS) between the chemotherapy group (35%), autologous transplant group (35%), 
and allogeneic transplant group (43%). Overall survival (OS) was marginally better after 
chemotherapy than following autologous or allogeneic transplant (52% vs. 43% vs. 46%). 
Twenty five percent of patients died after allogeneic transplant as compared to 14% 
following autologous transplant and 3% after chemotherapy. The subset analysis based on 
cytogenetic risk groups showed many methodological limitations of the study: a high 
proportion of patients did not receive the assigned therapy, which tends to reduce the 
measurable treatment effect in an intention-to-treat analysis.  
The EORTC–GIMEMA (European Organization for Research and Treatment of Cancer–
Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto) AML 8A trial59 showed no 
significant difference in overall survival after a median follow-up of 6 years among patients 
receiving allogeneic transplant from a sibling donor (overall survival: 48%) versus patients 
without a donor (40%, p=0.24; patients received autologous transplant or conventional 
chemotherapy). 
A higher incidence of early mortality after allogeneic transplant was counterbalanced by a 
lower incidence of late mortality. In the EORTC AML 10 trial60 these results were confirmed, 
with the exception of the high-risk group. In total, the survival rate at 4 years was 58.3% in 
the allogeneic, sibling donor group versus 50.8% in the autologous transplant group 
(p=0.18). In the high-risk group, in patients receiving allogeneic transplant the overall 
survival at 4 years (50.2%) was significantly better than after chemotherapy or autologous 
transplant (29.4%). In the standard-risk group and the low-risk group the results for overall 
survival were similar.  
However, the GOELAM (Groupe Ouest Est Leucemies Aigues Myeloblastiques) trial61 
reported no survival benefit for patients receiving an allogeneic transplant regardless of 
cytogenetic risk group. Interestingly, a trend toward better survival at 4 years following 
allogeneic transplant was more pronounced in the low-risk group (71.4% vs. 66.5%; p=0.6) 
and the high-risk group (41% vs. 30%, p=0.97) compared to the intermediate-risk group 
(40.5% vs.56.5%, p=0.08). The BGMT 87 trial62 reported overall survival only for the entire 
patient population and not stratified for risk groups. In patients receiving allogeneic 
transplant, 3-year survival was 65% in the donor group (n=36) and 50.9% in the no-donor 
group (n=60) receiving chemotherapy or autologous transplant. An analysis from all trials 
undertaken by the BGMT shows an improved survival only for the Intermediate and high-
risk population62. The MRC AML 10 trial by Burnett et al.63 evaluated 1063 patients on a 
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donor versus no-donor basis. All patients received four courses of induction chemotherapy 
followed by consolidation chemotherapy, after which patients with an HLA-matched sibling 
donor and in appropriate condition were scheduled to receive an allogeneic transplant. The 
remainder was randomized between autologous transplant and no further therapy. Sixty-
one percent of patients with a donor underwent transplant in first remission. In a donor 
versus no-donor analysis, significant benefit in disease-free survival and overall survival 
was seen only in the standard-risk cytogenetic group (DFS: 50% vs. 39%, p=0.001; OS: 55% 
vs. 44%, p=0.01). There were twice as many deaths in first remission among patients with a 
donor than among patients with no donor (19% vs. 9%; p<0.001). 
Recently, the results of three trials from the Dutch-Belgian Hemato-Oncology Cooperative 
Group and the Swiss Group for Clinical Cancer Research (HOVON/SAKK) based on a 
donor versus no-donor analysis in patients with AML in first remission were published as 
an individual patient data (IPD) analysis64. Based on the available IPD, the study included a 
total of 1032 patients from the trials. An HLA-identical sibling donor was available for 32% 
of patients, whereas 58% of patients lacked such a donor. Following risk-group analysis, 
disease free survival was significantly better for patients with available donor and standard- 
or high-risk profile (p=0.01 and p=0.003) and also better for patients younger than 40 years 
(p<0.001). However, the improved disease-free survival in the donor group did not translate 
into significantly better overall survival (p=0.07). Treatment-related mortality was 
significantly higher in the donor group (21% vs. 4%; p<0.001). 
Three meta-analyses investigated the apparent heterogeneity of clinical study results. 
Cornelissen et al. 64 performed a meta-analysis based on published data including more than 
4000 patients with AML in first remission enrolled in the HOVON/SAKK studies, the 
Medical Research Council (MRC) studies, the trials of the EORTC, and the BGMT studies. 
Disease-free survival and overall survival were analyzed, stratified for cytogenetic risk 
profile and age. Overall, transplant from a family donor statistically significantly prolonged 
disease-free survival in patients with intermediate- and high-risk profiles, but not in patients 
with a low-risk profile. This effect was pronounced but not restricted to patients below the 
age of 35 years. However, a benefit for overall survival in patients receiving stem cell 
transplant from a related donor was seen only in patients with intermediate- and low-risk 
disease up to the age of 35 years. In this analysis there was no evidence for improved 
outcomes in the favorable-risk group. These results are in accordance with the meta-analysis 
published by Koreth et al.6 in 3638 patients with AML in first CR. However, Yanada et al.65 
identified a beneficial effect of allogeneic transplant in these patients limited to the high-risk 
group. 
In summary, there is only a limited number of phase III trials evaluating the role of allo-SCT 
in patients with AML in first remission. The results of these trials are heterogeneous, and 
often limited to matched-related donor transplant. 
Transplant in relapse/progressive disease: it is generally accepted that the overall 
prognosis of patients with relapsed or progressive disease is poor. Especially in patients 
with initial duration of remission below 1 year, the success with standard regimens for 
inducing second remission is rare. Therefore, it is not surprising that in this situation most 
treatment guidelines recommend allogeneic transplant once a patient has achieved second 
remission. However, we did not identify any randomized trial in literature search 
addressing this clinical situation. In a phase II study, Schmid et al.66 treated 103 patients 
with refractory AML using dose-reduced chemotherapy followed by allogeneic transplant 
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from a related or unrelated donor. Refractory disease was defined as primary induction 
failure, relapse within 6 months after induction, or second relapse. Overall, 1 year after 
transplant the authors reported a disease free survival of 47% and an overall survival of 
54%. After a follow-up of 4 years, disease-free survival and overall survival declined to 30% 
and 32%. The risk for treatment failure was significantly increased in patients who received 
more than two cycles of chemotherapy before stem cell transplant, in patients with primary 
induction failure, bone marrow infiltration of more than 50% blasts, and more than a 
median of 215 days from diagnosis to transplant, or in patients with low CD34 cell count in 
the graft and if stem cells from a related donor were used. While the risk for non-relapse 
mortality increased when using an unrelated donor, age, sex, and underlying karyotype 
were not predictive for outcome. Minimal residual disease (MRD), mostly defined as the 
positive detection of genetic AML-specific mutations during microscopically diagnosed 
complete remission, is often examined in the follow-up period after induction therapy for 
leukemia. In small cohort of 45 patients, Laane et al.67 claimed a benefit by allogeneic 
transplant for those patients who were identified with detectable MRD after standard 
therapy. 
Reduced intensity conditioning: reduced intensity conditioning has broadened the use of 
allogeneic stem cell transplant to elderly patients and patients with comorbidities. 
Allogeneic transplant is no longer restricted to younger, fitter patients who are better able to 
tolerate the toxicities of a myeloablative regimen. The use of a less intensive approach 
potentially results in a reduced leukemia cell kill, which in turn increases the risk for relapse 
and a higher incidence of engraftment failure. Uncertainty remains regarding the frequency 
of graft-versus-host disease (GvHD) after reduced intensity allografts. Usually, a higher 
dose of immunosuppressive agents or the use of long-acting agents is recommended to 
reduce the rate of GvHD after transplant, thereby increasing the risk of relapse. In 
conclusion, there is an urgent need to define the role of allogeneic transplant in the mixed 
chimérisme setting. Unfortunately, published literature is often based on single centre 
experience with small numbers of patients. The Seattle experience is derived from large 
multicenter studies including a high number of patients. These studies have refined the 
optimal non-myeloablative treatment procedure, but they do not compare reduced intensity 
allografts with other treatment strategies68. 
At our knowledge, two randomized controlled studies, evaluating the role of reduced 
conditioning followed by allogeneic stem cell transplant for AML, have been published. 
Mothy et al.69 assigned 95 newly diagnosed adult patients with AML in first complete 
remission on a donor versus no-donor basis. All patients had a high-risk karyotype or 
clinical profile. Based on ‘biological’ randomization, patients with a matched sibling donor 
(n=35) were assigned to a transplant arm using reduced conditioning, whereas patients 
lacking such a donor (n=60) were assigned to standard treatment procedures. In an 
intention-to-treat analysis, 4-year disease-free survival was significantly higher in the donor 
group (54%) as compared to the no-donor group (30%; p=0.01). Furthermore, overall 
survival was significantly higher in the donor group as compared to the no-donor group 
(p=0.04). Transplant-related mortality was 12%. 
Estey and colleagues70 prospectively assessed the applicability of reduced intensity 
conditioning in patients with AML or MDS. Of 99 patients who entered complete remission 
after induction chemotherapy, 14 received an allogeneic transplant (13 siblings). The authors 
conducted a matched-pair analysis, comparing patients receiving chemotherapy with 
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patients who underwent transplant. Matching criteria were age, cytogenetics, and time 
between achieving CR and transplant. There was a significantly longer disease free survival 
in the transplanted patients, but the results for overall survival were similar between 
patients receiving transplant and patients receiving chemotherapy. 
In a large retrospective trial performed by the EBMT71, 315 patients with AML or MDS who 
received reduced intensity conditioning were compared with 407 patients who received a 
Myeloablative approach. In multivariate analysis, acute GvHD and transplant-related 
mortality were significantly decreased, and relapse incidence was significantly higher after 
reduced intensity conditioning. 
3.3 Autologous Stem Cell Transplantation (auto-SCT) 
For patients with AML who are unable to secure an acceptable HLA donor, the role of 
autologous stem cell transplantation (auto-SCT) has remained controversial. Its effectiveness 
remains unclear as, when analyzed on intention-to-treat strategies, a significant number do 
not undergo the procedure, whereas others seem to fail therapy from pre transplant 
recurrences. Recently, Novitzky et al.72 compared the outcome of patients in first remission 
of AML who actually underwent autologous or allogeneic transplantation. The choice for 
the type of graft was based on availability of HLA identical siblings. Patients received 
myeloablative conditioning followed by allogeneic or autologous cytokine mobilized 
peripheral blood stem cell transplantation. For prophylaxis of graft-versus-host disease 
(GVHD), grafts were incubated ex vivo with anti-CD52 antibodies and patients were 
prescribed cyclosporin until day 90. Patients were stratified by clinical and laboratory 
factors as well as cytogenetic risk. The endpoints were treatment-related mortality (TRM), 
disease-free survival (DFS), and overall survival (OS). The median presentation age for both 
transplant groups was 35 (14-60) years. Of the 112 consecutive patients achieving remission, 
autologous or allogeneic grafts were transplanted to 43 and 32 patients, respectively. There 
was no significant difference in the presentation clinical features, laboratory parameters, 
marrow morphology, or proportion of low and intermediate cytogenetic risk for both 
transplant options. Treatment mortality as well as relapse rate was similar (14% and 15%; 
39% and 27%, respectively). At a median of 1609 and 1819 post transplant days, 56% and 
63% in each group survived. In univariate analysis performance status, cytogenetic risk, 
morphologic features of dysplasia, blast count, and lactate dehydrogenase (LDH) were 
significant factors for survival. Although for the entire group there was no difference in 
survival between both modalities, all patients with unfavorable cytogenetics receiving an 
autologous graft died of disease recurrence (3-year survival 35% versus 0%; P = 0.05). They 
conclude that patients with AML who have low or intermediate cytogenetic risk undergoing 
myeloablative conditioning followed by autologous or allogeneic T cell-depleted stem cell 
transplantation appeared to have similar outcome. However, those with unfavorable 
karyotype are unlikely to be cured with autologous grafts and are candidates for 
experimental modalities.  
3.4 Other regimens for refractory /relapsed AML 
High-dose cytarabine (HiDAC) is commonly used for re-induction of relapsed or refractory 
AML. Recently, Thomas et al.73 et al reported a novel, timed-sequential regimen that takes 
advantage of synergy when mitoxantrone is given after cytarabine. Those patients received 
HiDAC/mitoxantrone regimen, with cytarabine at 3 g/m2 over four hours on days 1 and 5 
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plus mitoxantrone at 30 mg/m2 over one hour immediately following the HiDAC on days 1 
and 5. HiDAC/mitoxantrone induction was well tolerated and complete remission was 
achieved in 89%. of patients.  
To further enhance the CR rate in refractory/relapsed AML, the Japanese Adult Leukemia 
Study Group (JALSG) reported a phase II study of FLAGM (Fludarabine + High-Dose Ara-C 
+ G-CSF + mitoxantrone) in 41 patients with relapsed or refractory AML74. FLAGM yielded 
a 70% response rate in either relapsed or refractory AML patients. Although randomized 
studies are still needed, FLAGM appears to be a good option for the treatment of either 
relapsed or refractory AML patients. 
4. Conclusions: Future directions 
Achieving a cure for AML, even for younger adult patients with de novo AML, remains a 
challenge. While more than 70% of such patients will enter a first CR1 after induction 
chemotherapy, a substantial number experience disease relapse. Allo-SCT is a curative 
treatment option for younger patients with AML in CR1. However, concerns regarding allo-
SCT–related toxicity, and questions regarding its benefit, limit its use for patients who have 
attained an initial remission. Alternative therapies include intensive consolidation 
chemotherapy or auto-SCT. The current consensus, reflected in treatment guidelines of the 
National Comprehensive Cancer Network (V1.2009: available at http://www.nccn.org), is 
based on cytogenetic stratification into good-, intermediate-, and poor-risk AML. Compared 
with non-allo-SCT therapies, allo-SCT has significant relapse-free survival and overall 
survival benefit for intermediate- and poor-risk AML but not for good-risk AML in CR1. 
Prognostic markers, such as NPM1, Flt3-ITD, and cytogenetic abnormalities have made it 
possible to prospectively formulate aggressive treatment plans for unfavorable AML. If no 
Flt3-ITD mutation is present, CEBPα and NPM1 are generally associated with a favorable 
prognosis, and testing will be important in defining biologic subtypes that require less 
therapy. The presence of some of these mutations may modify the effect of others, so the 
establishment of a panel of significant markers may be needed to adequately assess risk and 
plan care. However, the long-term survival of AML with unfavorable factors remains 
unsatisfactory. Prolonged survival without curing high risk MDS/AML patients suggests 
that disease modification instead of cure of AML patients may be an alternative goal of 
treating elderly patients not suitable for aggressive therapy. New regimens and novel agents 
targeting specific pathways reviewed in this report may bring AML treatment into a new 
era. 
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